8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 23, 2026·SEC
AxoGen, Inc.(AXGN)Earnings, Financials & Key Ratios
AXGN•NASDAQ
Price updated Jun 19, 2026
AboutAxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.Show more
- Revenue$225M+20.2%
- EBITDA$344K-92.4%
- Net Income-$16M-57.6%
- EPS (Diluted)-0.34-47.8%
- Gross Margin74.31%-1.9%
- EBITDA Margin0.15%-93.7%
- Operating Margin-3.49%-98.6%
- Net Margin-6.97%-31.1%
- ROE-13.49%-35.1%
AXGN Key Insights
AxoGen, Inc. (AXGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Strong 5Y sales CAGR of 14.9%
- ✓Trading near 52-week high
- ✓Efficient asset utilization: 1.0x turnover
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 16.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AXGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AXGN Price & Volume
AxoGen, Inc. (AXGN) stock price & volume — 10-year historical chart
Loading chart...
AXGN Growth Metrics
AxoGen, Inc. (AXGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years23.48%
5 Years14.93%
3 Years17.57%
TTM22.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-339.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-292.02%
Return on Capital
10 Years-15.14%
5 Years-9.92%
3 Years-6.29%
Last Year-4.23%
AXGN Recent Earnings
AxoGen, Inc. (AXGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.07-41.7%
$0.12
Rev
$61M+6.2%
$58M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.07-21.2%
$0.09
Rev
$60M+1.5%
$59M
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.12+33.3%
$0.09
Rev
$60M+0.3%
$60M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.12+100.0%
$0.06
Rev
$57M-0.4%
$57M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.07vs $0.12-41.7% | $61Mvs $58M+6.2% |
| Q1 2026 | Feb 24, 2026 | $0.07vs $0.09-21.2% | $60Mvs $59M+1.5% |
| Q4 2025 | Oct 29, 2025 | $0.12vs $0.09+33.3% | $60Mvs $60M+0.3% |
| Q3 2025 | Aug 5, 2025 | $0.12vs $0.06+100.0% | $57Mvs $57M-0.4% |
Based on last 12 quarters of dataView full earnings history →
AXGN Peer Comparison
AxoGen, Inc. (AXGN) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TELA | 36.85M | 0.82 | -0.99 | 15.84% | -49.3% | -13.44% | 8.82 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 XTNT | 61.8M | 0.44 | 14.69 | 14.21% | 1.5% | 3.68% | 0.56 | |
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 ANIK | 193.24M | 14.42 | -18.97 | -5.91% | -9.52% | -7.74% | 0.17 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare AXGN vs Peers
AxoGen, Inc. (AXGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AXGN Income Statement
AxoGen, Inc. (AXGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 60.43M | 83.94M | 106.71M | 112.3M | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M | 238.1M |
Revenue Growth % | 47% | 38.91% | 27.13% | 5.24% | 13.41% | 8.81% | 14.74% | 17.81% | 20.21% | 22.41% |
Cost of Goods Sold | 9.31M | 12.92M | 17.35M | 21.58M | 22.93M | 29.77M | 37.14M | 45.36M | 57.85M | 59.5M |
COGS % of Revenue | 15.41% | 15.4% | 16.26% | 19.22% | 18.01% | 21.49% | 23.36% | 24.21% | 25.69% | - |
Gross Profit | 51.11M▲ 0% | 71.01M▲ 38.9% | 89.36M▲ 25.8% | 90.72M▲ 1.5% | 104.43M▲ 15.1% | 108.81M▲ 4.2% | 121.87M▲ 12.0% | 141.98M▲ 16.5% | 167.35M▲ 17.9% | 178.61M▲ 0% |
Gross Margin % | 84.59% | 84.6% | 83.74% | 80.78% | 81.99% | 78.51% | 76.64% | 75.79% | 74.31% | 75.01% |
Gross Profit Growth % | 47.56% | 38.93% | 25.84% | 1.52% | 15.11% | 4.2% | 12% | 16.5% | 17.87% | - |
Operating Expenses | 59.07M | 91.51M | 120.77M | 113.9M | 129.84M | 138.52M | 143.33M | 145.26M | 175.2M | 187.63M |
OpEx % of Revenue | 97.75% | 109.03% | 113.17% | 101.43% | 101.95% | 99.95% | 90.14% | 77.54% | 77.8% | - |
Selling, General & Admin | 52.37M | 79.74M | 103.25M | 96.06M | 105.67M | 112.89M | 115.99M | 117.5M | 142.32M | 153.32M |
SG&A % of Revenue | 86.66% | 95% | 96.76% | 85.53% | 82.97% | 81.46% | 72.95% | 62.72% | 63.19% | - |
Research & Development | 6.7M | 11.77M | 17.51M | 17.85M | 24.18M | 25.63M | 27.34M | 27.77M | 32.88M | 34.31M |
R&D % of Revenue | 11.09% | 14.03% | 16.41% | 15.89% | 18.98% | 18.49% | 17.19% | 14.82% | 14.6% | - |
Other Operating Expenses | -30.77K | -28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -7.95M▲ 0% | -20.5M▼ 157.8% | -31.41M▼ 53.2% | -23.18M▲ 26.2% | -25.42M▼ 9.6% | -29.71M▼ 16.9% | -21.46M▲ 27.8% | -3.29M▲ 84.7% | -7.85M▼ 138.8% | -9.02M▲ 0% |
Operating Margin % | -13.16% | -24.42% | -29.43% | -20.64% | -19.96% | -21.44% | -13.5% | -1.75% | -3.49% | -3.79% |
Operating Income Growth % | 2.2% | -157.82% | -53.2% | 26.19% | -9.64% | -16.88% | 27.75% | 84.68% | -138.79% | - |
EBITDA | -7.38M | -19.65M | -28.53M | -19.72M | -20.68M | -24.85M | -15.91M | 4.55M | 344K | -2.53M |
EBITDA Margin % | -12.22% | -23.41% | -26.73% | -17.56% | -16.23% | -17.93% | -10% | 2.43% | 0.15% | -1.06% |
EBITDA Growth % | 4.01% | -166.08% | -45.19% | 30.87% | -4.83% | -20.21% | 35.99% | 128.6% | -92.44% | -134.05% |
D&A (Non-Cash Add-back) | 566.6K | 851K | 2.88M | 3.46M | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M | 6.49M |
EBIT | -7.98M | -21.19M | -29.09M | -22.73M | -25.63M | -28.32M | -18.88M | -1.76M | -8M | -795K |
Net Interest Income | -2.46M | -1.21M | -40K | -1.05M | -1.36M | -624K | -2.83M | -8.21M | -7.7M | -14.15M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 450K |
Interest Expense | 2.46M | 1.21M | 40K | 1.05M | 1.36M | 624K | 2.83M | 8.21M | 7.7M | 14.6M |
Other Income/Expense | -2.49M | -1.9M | 2.27M | -604K | -1.57M | 759K | -254K | -6.68M | -7.85M | -22.43M |
Pretax Income | -10.45M▲ 0% | -22.4M▼ 114.4% | -29.14M▼ 30.1% | -23.79M▲ 18.4% | -26.98M▼ 13.4% | -28.95M▼ 7.3% | -21.72M▲ 25.0% | -9.96M▲ 54.1% | -15.7M▼ 57.6% | -31.45M▲ 0% |
Pretax Margin % | -17.29% | -26.68% | -27.3% | -21.18% | -21.19% | -20.89% | -13.66% | -5.32% | -6.97% | -13.21% |
Income Tax | 2.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -23.88% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -10.45M▲ 0% | -22.4M▼ 114.4% | -29.12M▼ 30.0% | -23.79M▲ 18.3% | -26.98M▼ 13.4% | -28.95M▼ 7.3% | -21.72M▲ 25.0% | -9.96M▲ 54.1% | -15.7M▼ 57.6% | -31.45M▲ 0% |
Net Margin % | -17.29% | -26.68% | -27.29% | -21.18% | -21.19% | -20.89% | -13.66% | -5.32% | -6.97% | -13.21% |
Net Income Growth % | 27.52% | -114.42% | -30.03% | 18.32% | -13.45% | -7.27% | 24.98% | 54.12% | -57.6% | -339.1% |
Net Income (Continuing) | -10.45M | -22.4M | -29.14M | -23.79M | -26.98M | -28.95M | -21.72M | -9.96M | -15.7M | -31.45M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.31▲ 0% | -0.60▼ 93.5% | -0.74▼ 23.3% | -0.60▲ 18.9% | -0.65▼ 8.3% | -0.69▼ 6.2% | -0.51▲ 26.1% | -0.23▲ 54.9% | -0.34▼ 47.8% | -0.61▲ 0% |
EPS Growth % | 34.04% | -93.55% | -23.33% | 18.92% | -8.33% | -6.15% | 26.09% | 54.9% | -47.83% | -292.02% |
EPS (Basic) | -0.31 | -0.60 | -0.74 | -0.60 | -0.65 | -0.69 | -0.51 | -0.23 | -0.34 | - |
Diluted Shares Outstanding | 33.32M | 37.13M | 39.23M | 39.97M | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M | 51.59M |
Basic Shares Outstanding | 33.32M | 37.13M | 39.23M | 39.97M | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M | 51.59M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AXGN Balance Sheet
AxoGen, Inc. (AXGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 55.74M | 150.95M | 135.02M | 145.25M | 127.05M | 98.08M | 88M | 99.22M | 120.42M | 184.71M |
Cash & Short-Term Investments | 36.51M | 116.61M | 96.51M | 103.97M | 84.09M | 48.79M | 31.02M | 33.48M | 35.55M | 82.65M |
Cash Only | 36.51M | 24.29M | 35.72M | 48.77M | 32.76M | 15.28M | 31.02M | 27.55M | 35.55M | 82.65M |
Short-Term Investments | 0 | 92.31M | 60.79M | 55.2M | 51.33M | 33.51M | 0 | 5.93M | 0 | 0 |
Accounts Receivable | 11.06M | 15.32M | 16.94M | 17.62M | 18.16M | 22.19M | 25.15M | 24.11M | 26.17M | 28.31M |
Days Sales Outstanding | 66.84 | 66.62 | 57.96 | 57.26 | 52.04 | 58.43 | 57.72 | 46.97 | 42.41 | 43.42 |
Inventory | 7.32M | 11.98M | 13.86M | 12.53M | 16.69M | 18.91M | 23.02M | 33.18M | 42.37M | 46.07M |
Days Inventory Outstanding | 286.77 | 338.42 | 291.62 | 211.9 | 265.71 | 231.75 | 226.21 | 267.01 | 267.33 | 254.29 |
Other Current Assets | 853.38K | 6M | 6M | 6.84M | 6.25M | 6.25M | 6M | 8.45M | 16.33M | 27.67M |
Total Non-Current Assets | 3.13M | 9.22M | 19.62M | 56.13M | 80.97M | 97.31M | 108.82M | 104.51M | 101.27M | 104.78M |
Property, Plant & Equipment | 2.2M | 8.04M | 18.11M | 54.08M | 78.12M | 93.66M | 104.29M | 98.93M | 94.52M | 97.32M |
Fixed Asset Turnover | 27.50x | 10.44x | 5.89x | 2.08x | 1.63x | 1.48x | 1.52x | 1.89x | 2.38x | 2.49x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 936.99K | 1.18M | 1.51M | 2.05M | 2.86M | 3.65M | 4.53M | 5.58M | 6.75M | 7.27M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 192K |
Total Assets | 58.87M▲ 0% | 160.17M▲ 172.1% | 154.64M▼ 3.5% | 201.38M▲ 30.2% | 208.02M▲ 3.3% | 195.39M▼ 6.1% | 196.83M▲ 0.7% | 203.73M▲ 3.5% | 221.69M▲ 8.8% | 289.49M▲ 0% |
Asset Turnover | 1.03x | 0.52x | 0.69x | 0.56x | 0.61x | 0.71x | 0.81x | 0.92x | 1.02x | 1.02x |
Asset Growth % | 26.99% | 172.06% | -3.45% | 30.22% | 3.3% | -6.07% | 0.74% | 3.51% | 8.82% | 77.85% |
Total Current Liabilities | 13.72M | 13.04M | 20.88M | 22.83M | 24.29M | 23.75M | 30.43M | 30.61M | 23.56M | 26.01M |
Accounts Payable | 3.24M | 4.52M | 8.26M | 4.6M | 5.92M | 8.96M | 11.77M | 8.01M | 0 | 0 |
Days Payables Outstanding | 126.92 | 127.58 | 173.82 | 77.75 | 94.28 | 109.89 | 115.7 | 64.44 | - | 34.92 |
Short-Term Debt | 735.02K | 28K | 1.74M | 863K | 0 | 0 | 0 | 0 | 2.37M | 2.12M |
Deferred Revenue (Current) | 31.67K | 18K | 14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.94M | 2M | 7.62M | 12.73M | 9.67M | 0 | 0 | 18.58M | 21.18M | 23.9M |
Current Ratio | 4.06x | 11.57x | 6.47x | 6.36x | 5.23x | 4.13x | 2.89x | 3.24x | 5.11x | 7.10x |
Quick Ratio | 3.53x | 10.65x | 5.80x | 5.81x | 4.54x | 3.33x | 2.14x | 2.16x | 3.31x | 5.33x |
Cash Conversion Cycle | 226.69 | 277.47 | 175.75 | 191.42 | 223.47 | 180.3 | 168.24 | 249.54 | - | 262.79 |
Total Non-Current Liabilities | 19.97M | 147K | 1.61M | 55.4M | 71.18M | 70.64M | 70.73M | 69.21M | 69.28M | 18.67M |
Long-Term Debt | 19.91M | 35K | 1.59M | 32.03M | 44.82M | 45.71M | 46.6M | 47.5M | 16.87M | 18.53M |
Capital Lease Obligations | 0 | 0 | 1.59M | 20.87M | 20.8M | 20.41M | 21.14M | 19.22M | 0 | 35.46M |
Deferred Tax Liabilities | -164K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 70K | -1.59M | 2.5M | 5.56M | 4.52M | 2.99M | 2.49M | 52.41M | 140K |
Total Liabilities | 33.69M | 13.19M | 22.49M | 78.23M | 95.47M | 94.39M | 101.16M | 99.82M | 92.84M | 44.68M |
Total Debt | 24.64M | 63K | 4.93M | 54.63M | 67.45M | 67.43M | 69.29M | 68.69M | 19.24M | 20.64M |
Net Debt | -11.87M | -24.23M | -30.8M | 5.86M | 34.7M | 52.14M | 38.27M | 41.13M | -16.31M | -62.01M |
Debt / Equity | 0.98x | 0.00x | 0.04x | 0.44x | 0.60x | 0.67x | 0.72x | 0.66x | 0.15x | 0.08x |
Debt / EBITDA | - | - | - | - | - | - | - | 15.10x | 55.94x | -8.16x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 9.04x | -47.40x | 24.50x |
Interest Coverage | -3.24x | -17.54x | -727.38x | -21.57x | -18.90x | -45.39x | -6.66x | -0.21x | -1.04x | -0.05x |
Total Equity | 25.18M▲ 0% | 146.98M▲ 483.7% | 132.15M▼ 10.1% | 123.15M▼ 6.8% | 112.55M▼ 8.6% | 101M▼ 10.3% | 95.67M▼ 5.3% | 103.91M▲ 8.6% | 128.85M▲ 24.0% | 244.81M▲ 0% |
Equity Growth % | 68.77% | 483.68% | -10.09% | -6.81% | -8.61% | -10.26% | -5.28% | 8.62% | 24% | 195.21% |
Book Value per Share | 0.76 | 3.96 | 3.37 | 3.08 | 2.73 | 2.40 | 2.23 | 2.35 | 2.80 | 4.75 |
Total Shareholders' Equity | 25.18M | 146.98M | 132.15M | 123.15M | 112.55M | 101M | 95.67M | 103.91M | 128.85M | 244.81M |
Common Stock | 343.5K | 389K | 396K | 406K | 417K | 424K | 431K | 441K | 472K | 532K |
Retained Earnings | -128.33M | -150.73M | -179.86M | -203.65M | -230.63M | -259.58M | -281.3M | -291.26M | -306.96M | -326.55M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.29M | -2.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AXGN Cash Flow Statement
AxoGen, Inc. (AXGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.24M | -17.86M | -19.87M | -9.63M | -13.4M | -16.07M | -5.72M | 4.54M | 812K | 15.56M |
Operating CF Margin % | -15.29% | -21.28% | -18.62% | -8.57% | -10.53% | -11.59% | -3.59% | 2.42% | 0.36% | - |
Operating CF Growth % | 17.55% | -93.36% | -11.25% | 51.56% | -39.26% | -19.85% | 64.42% | 179.34% | -82.09% | 114.87% |
Net Income | -10.45M | -22.4M | -29.14M | -23.79M | -26.98M | -28.95M | -21.72M | -9.96M | -15.7M | -31.45M |
Depreciation & Amortization | 566.6K | 851K | 2.88M | 3.46M | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M | 8.56M |
Stock-Based Compensation | 3.61M | 7.61M | 10.3M | 8.47M | 10.92M | 15.59M | 14.42M | 15.91M | 30.11M | 34.05M |
Deferred Taxes | 223.32K | 4.38M | 0 | 2.21M | 3.37M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 246.56K | 81K | 1.53M | 232K | 831K | 2M | 415K | 797K | 2.83M | 18.46M |
Working Capital Changes | -3.44M | -8.38M | -5.45M | -209K | -6.28M | -9.56M | -4.39M | -10.04M | -24.62M | -14.05M |
Change in Receivables | -3.24M | -5.11M | -2.14M | -635K | -499K | -4.64M | -2.69M | 392K | -2.46M | -2.11M |
Change in Inventory | -1.86M | -6.01M | -3.77M | -910K | -7.48M | -3.66M | -6.05M | -10.16M | -9.19M | -10.57M |
Change in Payables | 1.93M | 3.71M | 2.92M | 4.96M | -270K | 660K | 6.51M | 125K | -7.16M | 1.35M |
Cash from Investing | -1.29M | -98.19M | 27.27M | -16.96M | -23.65M | -3.2M | 19.25M | -10.3M | -5.32M | -22.62M |
Capital Expenditures | -1.29M | -6.6M | -4.66M | -22.6M | -28.4M | -21.25M | -13.87M | 0 | -3.75M | -6.28M |
CapEx % of Revenue | 2.14% | 7.87% | 4.37% | 20.12% | 22.3% | 15.34% | 8.72% | 2.41% | 1.66% | 2.64% |
Acquisitions | 0 | 321K | 0 | 692K | -589K | 3.2M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -187K | -321K | -562K | -692K | 1.54M | -3.2M | -1.05M | -10.3M | -1.85M | -1.62M |
Cash from Financing | 17.02M | 109.84M | 4.03M | 40.47M | 20.45M | 1.79M | 1.95M | 2.29M | 10.5M | 67.62M |
Debt Issued (Net) | -21K | -22.51M | 29K | 34.99M | 14.98M | -12K | -10K | -10K | -32K | -69.79M |
Equity Issued (Net) | 15.89M | 0 | 0 | 3.5M | 5.47M | 1.81M | 1.96M | 2.3M | 10.53M | 143.23M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 1.15M | 132.35M | 4M | 1.99M | 0 | 0 | 0 | 0 | 0 | -5.82M |
Net Change in Cash | 6.49M▲ 0% | -6.21M▼ 195.7% | 11.43M▲ 284.0% | 13.88M▲ 21.5% | -16.6M▼ 219.6% | -17.47M▼ 5.2% | 15.49M▲ 188.7% | -3.47M▼ 122.4% | 5.99M▲ 272.6% | 60.56M▲ 0% |
Free Cash Flow | -10.53M▲ 0% | -24.46M▼ 132.3% | -25.1M▼ 2.6% | -32.22M▼ 28.4% | -41.8M▼ 29.7% | -37.32M▲ 10.7% | -20.63M▲ 44.7% | 11K▲ 100.1% | -2.93M▼ 26763.6% | 8.93M▲ 0% |
FCF Margin % | -17.43% | -29.15% | -23.52% | -28.69% | -32.82% | -26.93% | -12.98% | 0.01% | -1.3% | 3.75% |
FCF Growth % | 15.04% | -132.34% | -2.59% | -28.39% | -29.74% | 10.73% | 44.71% | 100.05% | -26763.64% | 4781.42% |
FCF per Share | -0.32 | -0.66 | -0.64 | -0.81 | -1.01 | -0.89 | -0.48 | 0.00 | -0.06 | 0.17 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.80x | 0.68x | 0.40x | 0.50x | 0.55x | 0.26x | -0.46x | -0.05x | -0.28x |
Interest Paid | 0 | 0 | 34K | 0 | 0 | 0 | 0 | 0 | 0 | 1.53M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AXGN Key Ratios
AxoGen, Inc. (AXGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -52.09% | -26.02% | -20.87% | -18.63% | -22.9% | -27.11% | -22.08% | -9.99% | -13.49% | -20.74% |
Return on Invested Capital (ROIC) | -52.93% | -22.6% | -21.02% | -15.09% | -13.8% | -14.83% | -11.21% | -1.77% | -4.57% | -4.4% |
Gross Margin | 84.59% | 84.6% | 83.74% | 80.78% | 81.99% | 78.51% | 76.64% | 75.79% | 74.31% | 75.01% |
Net Margin | -17.29% | -26.68% | -27.29% | -21.18% | -21.19% | -20.89% | -13.66% | -5.32% | -6.97% | -13.21% |
Debt / Equity | 0.98x | 0.00x | 0.04x | 0.44x | 0.60x | 0.67x | 0.72x | 0.66x | 0.15x | 0.08x |
Interest Coverage | -3.24x | -17.54x | -727.38x | -21.57x | -18.90x | -45.39x | -6.66x | -0.21x | -1.04x | -0.05x |
FCF Conversion | 0.88x | 0.80x | 0.68x | 0.40x | 0.50x | 0.55x | 0.26x | -0.46x | -0.05x | -0.28x |
Revenue Growth | 47% | 38.91% | 27.13% | 5.24% | 13.41% | 8.81% | 14.74% | 17.81% | 20.21% | 22.41% |
Related:AXGN Dividend History·AXGN Revenue History·AXGN Price History·AXGN P/E History·AXGN Financial Ratios·AXGN Institutional Holders
AXGN SEC Filings & Documents
AxoGen, Inc. (AXGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
AXGN Frequently Asked Questions
AxoGen, Inc. (AXGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AxoGen, Inc. (AXGN) reported $238.1M in revenue for fiscal year 2025. This represents a 1718% increase from $13.1M in 1996.
AxoGen, Inc. (AXGN) grew revenue by 20.2% over the past year. This is strong growth.
AxoGen, Inc. (AXGN) reported a net loss of $31.5M for fiscal year 2025.
Dividend & Returns
AxoGen, Inc. (AXGN) has a return on equity (ROE) of -13.5%. Negative ROE indicates the company is unprofitable.
AxoGen, Inc. (AXGN) generated $8.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.